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The ATP-dependent protease FtsH (HflB) complexed with HflKC participates in post-translational control of the lysis-lysogeny
decision of bacteriophage lambda by rapid degradation of lambda CII. Both phage-encoded proteins, the CII transcription
activator and the CIII polypeptide, are required for efficient lysogenic response. The conserved CIII is both an inhibitor and
substrate of FtsH. Here we show that the protease inhibitor CIII is present as oligomeric amphipathic a helical structures and
functions as a competitive inhibitor of FtsH by preventing binding of the CII substrate. We identified single alanine
substitutions in CIII that abolish its activity. We characterize a dominant negative effect of a CIII mutant. Thus, we suggest that
CIII oligomrization is required for its function. Real-time analysis of CII activity demonstrates that the effect of CIII is not seen in
the absence of either FtsH or HflKC. When CIII is provided ectopically, CII activity increases linearly as a function of the
multiplicity of infection, suggesting that CIII enhances CII stability and the lysogenic response. FtsH function is essential for
cellular viability as it regulates the balance in the synthesis of phospholipids and lipopolysaccharides. Genetic experiments
confirmed that the CIII bacteriostatic effects are due to inhibition of FtsH. Thus, the early presence of CIII following infection
stimulates the lysogenic response, while its degradation at later times ensures the reactivation of FtsH allowing the growth of
the established lysogenic cell.
Citation: Kobiler O, Rokney A, Oppenheim AB (2007) Phage Lambda CIII: A Protease Inhibitor Regulating the Lysis-Lysogeny Decision. PLoS ONE 2(4):
e363. doi:10.1371/journal.pone.0000363
INTRODUCTION
Proteolysis of key regulatory factors is an important control
element of gene activity both in eukaryotic and prokaryotic cells.
In bacteria degradation by ATP-dependent proteases, belonging
to the AAA+ superfamily, participates in regulation of many
developmental pathways: the heat shock response, starvation
adaptation, DNA damage repair, capsular polysaccharide bio-
synthesis, sporulation and control of bacteriophage development
[1–5]. Specific adaptor proteins are known to modify the
interaction of substrates with ATP-dependent proteases (reviewed
in [6–8]). However, there are only three known intracellular
inhibitory polypeptides. The phage T4 PinA protein inhibits the
Lon protease [9], and both the Bacillus species sporulation
regulator SpoVM [10] and the phage l CIII [11,12] inhibit the
FtsH protease. Both FtsH inhibitors, SpoVM and CIII, were
predicted to form amphipathic a helices and are degraded by FtsH
[12–14].
The FtsH protease is the only essential ATP-dependent protease
in E. coli. [15,16]. It is a membrane-bound homohexamer enzyme
made of three major domains: a trans-membrane domain, an
ATPase domain and a protease domain. FtsH is complexed with
HflKC forming an FtsH6-HflKC6 holoenzyme, which is present in
the cell in less than 100 copies. FtsH degrades membrane proteins
[17] and a number of cytoplasmic proteins such as LpxC, s32,
SsrA-tagged proteins and the bacteriophage lCII and CIII pro-
teins. Degradation of LpxC by FtsH is required for Escherichia coli
viability, as the levels of LpxC are essential for maintaining the
balance in the synthesis of phospholipids and lipopolysaccarides.
Bacteriophage l infection may activate either the lytic or the
lysogenic developmental pathway [18,19]. In l infection, physi-
ological conditions as low temperature [20], starvation of the cells
and high multiplicity of infection (MOI) [21] are known to favor
lysogeny. A few phage functions are specifically required for the
lysogenic response [22,23]. The CII transcriptional activator,
which is a key regulator of the lysis-lysogeny decision, induces
three promoters essential for the lysogenic pathway. CII is
required for the initial synthesis of the CI repressor from the pE
promoter and of the integration protein Int, from the pI promoter.
In addition, CII activates the paQ promoter and thus inhibits the
Q antiterminator essential for lytic gene expression. The CII
transcriptional activator is subjected to multilevel controls [19].
High levels of the CII protein, that are required for the activation
of the lysogenic developmental pathway, are facilitated by l CIII,
a 54-residue peptide which protects CII from rapid degradation by
FtsH [11,12]. The CIII protein was also shown to induce the heat
shock response by stabilizing s32 [13]. A 24-amino acid (residues
14–37) region of the l CIII protein, which is essential and
sufficient for CIII activity, was predicted to form a conserved
amphipathic a helix [13]. In vitro assays in a purified system
showed that CIII inhibits FtsH proteolysis activity and can be
degraded by the enzyme [12].
In this work we present novel findings on the structure and
mechanism of action of CIII in vitro and analyze its in vivo functions.
We demonstrate that CIII possesses an amphipathic alpha helical
structure. It is present in solution as higher order complex struc-
tures and acts as a competitive inhibitor of FtsH by preventing the
binding of CII. We further show that both FtsH and HlfKC
contribute to the down-regulation of CII activity following
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fusions demonstrate that CIII levels have a profound influence on
CII stability in vivo suggesting that CIII may control the lysis-
lysogeny decision. Finally, we demonstrate that the cause for the
bacteriostatic effect of CIII is inhibition of FtsH that affects the
balance in lipid membrane composition.
RESULTS
Conservation of CIII
The recent surge in sequencing of bacteriophages and of
prophages yielded an increasing number of conserved cIII
encoding genes. These can be classified into two classes: the l
CIII protein homologs and the HK022 CIII homologs (Figure 1A).
The larger l CIII group includes the phage 933W, which is the
best studied phage encoding for the Stx2 Shiga toxin (see [24]).
The HK022 CIII [25] group includes in addition, only HK097
and H-19B that encode for the Stx1 Shiga toxin. In figure 1A only
the HK022 CIII is shown as all three proteins have identical
sequence. The 24-amino acid (residues 14–37 underlined in
figure 1) region essential for l CIII activity [13] is the most
conserved sequence. This sequence was previously predicted to
form an amphipathic a helix containing a short coiled coil
structure [13]. In this region the a and d coiled coil positions are
mostly occupied by hydrophobic amino acids. Additionally,
a relatively high number of conserved positive and negative
residues are found. Interestingly, five spaced residues, including
two glycines, are highly conserved at the amino terminus. The
function of these residues is not known.
The other FtsH inhibitors, the conserved SpoVM from Bacillus
species, are also predicted to form an amphipathic a helix.
Figure 1B shows alignment of CIII with the SpoVM peptides. The
alignment suggests that these inhibitors are structurally similar.
Search of the genome database for CIII-related peptides, using
the region essential for CIII activity as query, yielded one protein
domain of unknown function, DUF1737 (Figure 1C). This domain
Figure 1. Conservation of CIII in phage and bacteria. The multi sequences alignment was done using the ClustalX (version 1.81) program. Conserved
or partially conserved residues are colored according to their biochemical properties. The essential region for CIII activity is underlined and the
positions predicted coiled coil (by the MARCOIL) is marked above the sequence. (A) Alignment of CIII proteins from different phages and prophages
(represented by the phage name or the bacterial strain carrying the prophage, respectively). CIII proteins were collected from the BLAST program by
using the lambda CIII sequence as a query for the non-redundant database. A separate search using the HK022 CIII sequence was done. The HK022
CIII sequence is identical to that of HK097A and H-19B. A complete list of all the phages and prophages in which CIII homologs were recognized, is
presented in the supplementary material. (B) Alignment of CIII and SpoVM proteins was carried out with the lambda CIII protein aligned with three
SpoVM proteins from different Bacillus strains. (C) Alignment of CIII and YjhS hypothetical proteins that carry the DUF1737 and DUF303, was carried
out. The three YjhS-like proteins were derived from different Shigella toxin carrying phages. The HP stands for hypothetical protein without a specific
name.
doi:10.1371/journal.pone.0000363.g001
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open reading frames, and is joined to a domain of unknown
function, DUF303, in 42 cases. These open reading frames are
found downstream to Shiga toxin encoding genes in Stx
converting phages, indicating a possible role in bacterial virulence.
Purified CIII possesses an a helical structure and is
able to oligomerize
A highly purified preparation of His6-CIII was prepared as
previously described [12] (Figure 2A). The CIII structure was
analyzed in solution by circular dichroism (CD) at 37uC
(Figure 2B). Analysis of the CD spectra suggests that the protein
forms an a helical structure. Furthermore the a helical content
increases from 56% to 78% as the concentrations of CIII increases
from 3.5 mMt o4 0mM, suggesting that interactions between CIII
protomers contribute to secondary structure stability. Figure 3A
shows that multiple oligomers can be visualized using western blot
analysis and that CIII oligomers can partially resist electrophoresis
in the presence of SDS. To determine the oligomerization state of
CIII in solution, His6-CIII was chemically crosslinked by glutaral-
dehyde, the oligomers separated by electrophoresis and visualized
by His6 antibodies (Figure 3B). A ladder of ordered protein bands
indicating increasing numbers of monomers up to a 12mer could
be clearly detected. We conclude that CIII is present in solution
in multiple oligomeric states. Furthermore, we detected CIII
oligomers by electrophoresis of cells following l infection (data not
shown).
CIII functions as a competitive inhibitor of FtsH
To determine the mechanism of FtsH inhibition by CIII we
performed an in vitro proteolysis assay of CII in the presence of
increasing CIII to FtsH ratios (Figure 4A). We found a linear
inverse correlation between CIII concentration and the ability of
FtsH to degrade CII. These results suggest a simple dose-
dependent inhibition. We found that degradation of 1 mM CII is
completely inhibited by 30 mM CIII whereas for 4 mM CII, more
than 60 mM CIII are required for complete inhibition (Figure 4B).
These findings suggest a competitive inhibitory mechanism. To
test if CIII competes with CII at the level of binding to FtsH we
carried out cross-linking experiments. We found that CIII inhibits
the formation of CII-FtsH complexes (Figure 4C and D). The
concentrations of CIII required for inhibition of CII binding to
FtsH correlate with the levels needed to inhibit CII proteolysis,
suggesting that CIII acts by competing for the substrate recogni-
tion site of FtsH. During the proteolysis assay the CIII concentra-
tions also decrease, therefore when comparing the proteolysis
assay to the binding assay higher levels of CIII are required in the
former to obtain similar inhibition.
The ftsH and hflKC mutant strains allow over
expression of CII independent of CIII
Following phage infection, CII and CIII are required for efficient
lysogeny. CII induces the expression of the CI repressor from the
pE promoter. FtsH, which is found in holoenzyme complexes with
HflKC, degrades both CII and CIII. It was shown that mutations
in ftsH or hflKC promote high frequency of lysogenization that is
independent of CIII, while mutations in the cII gene allow for
phage growth [26,27]. To obtain quantitative data on the role of
CIII in the absence of FtsH or HflK we carried out infections of
bacterial mutant strains with l wt and mutants under conditions
that greatly favor the lysogenic pathway. CII activity was assayed
by a real-time kinetic readout from the pE-GFP reporter (Figure 5,
blue lines) [28]. In parallel we assayed the lytic pathway by
measuring Q activity using the pR9-tR9-GFP reporter (Figure 5,
red lines) [28]. The results show that levels of CII in both ftsH
2 or
hflKC
2 strains are much higher than those obtained following
infection of the isogenic wild-type host. Furthermore, both host
mutants show efficient suppression of the cIII mutation, suggesting
that in the absence of FtsH and HflKC, CIII is dispensable.
However, the loss of CII activity, following a peak, suggests that
additional proteases participate in the degradation of CII.
We have previously shown that the Q function, measured from
the pR9-tR9-GFP, is very low under conditions favoring the
lysogenic pathway, mainly due to the presence of high CII levels
[28]. Consistent with our previous findings, Figure 5 shows that
infections with a l cII
2 mutant phage lead to high Q activity. Q
Figure 2. Circular dichroism of CIII. (A) 200 pmol of purified His6-CIII
(right lane) were loaded on 4–12% NuPAGE (invitrogen) and visualized
by Coomassie staining. On the left lane protein size marker was loaded
(sizes 49, 38, 28, 14, 6 and 3 kDa). (B) The Circular dichroism spectrum
(wavelengths 195–255 nm) of the purified His6-CIII at 3.5 mM (light
gray), 27 mM (dark gray) and 40 mM (black).
doi:10.1371/journal.pone.0000363.g002
Figure 3. Oligomerization of CIII. (A)1 0ml of different concentrations
of purified His6-CIII protein were loaded on 4–12% NuPAGE (invitrogen)
and visualized by western blotting using commercial antibodies against
the His6 tag. (B)1 0mM of His6-CIII was incubated in the presence (lanes
2,3) or absence (lane 1) of 0.25% Glutaraldehyde and the cross-linking
reaction was stopped after 1 or 5 minutes by 200 mM Glycine (lanes 2
and 3 respectively). The reactions were loaded on 4–12% NuPAGE
(invitrogen) and visualized by western blotting using commercial
antibodies against the His6 tag.
doi:10.1371/journal.pone.0000363.g003
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suggesting that the effect of these proteins on the lytic pathway is
mediated mainly by CII. We note however, that infections of the
hflK mutant result in significantly lower levels of Q activity.
Presently, we do not have a simple explanation for this result.
The level of CIII activity controls the output from the
CII-dependent pE promoter
Genetic experiments indicated that approximately 3-fold increase
in the translation of CIII greatly favors the lysogenic response [29].
To determine how the continuous supply of CIII would affect CII
activity we infected cells carrying a double plasmid system with l
strains. A compatible plasmid (pCTCIII) carrying the cIII gene
under the pTac inducible promoter was introduced into wild type
cells carrying one of the l promoter-gfp fusion plasmids. Following
infection of these cells in the presence or absence of the IPTG
inducer, the CII and Q activities were monitored (Figure 6, blue
and red lines respectively). The results show that ectopic supply of
CIII increases both the time and the amplitude of CII activity
expressed by the infecting phages. As expected, the effect of CIII
supplied in trans on CII and Q activities is much more dramatic in
infection with a l cIII
2 mutant than infection by the wild-type
phage. Interestingly, ectopic addition of CIII reduces the output
signal from the pR9-tR9-GFP plasmid even in the absence of CII.
It is possible that by inducing the heat-shock response CIII can
further modulate Q antitermination activity [13]. Consistent with
this hypothesis, we found that following infection either by l c+ or
by l cII
2 at 42uC, a significant decrease in Q activity was observed
(data not shown).
The experimental setup allowed us to test the dependence of
CII activity on the number of cII copies carried by the infecting
phages in the presence of equal levels of CIII that is ectopically
expressed. The results show a linear increase in CII activity as
function of MOI (Figure 7). By comparing infection of l c+ and l
cIII
2 phages, we found that the amount of CIII made from the
infecting phage has an effect when MOI is greater than 4, and
little or no effect at low MOI. However, CIII supplied from the
plasmid increases CII function at all MOI’s, allowing the phage to
follow the lysogenic pathway even at low MOI. These results
indicate that CIII can modulate the phage genetic network.
CIII dominant negative mutant
We hypothesized that CIII oligomerization is required for efficient
FtsH inhibition. We thus predict that it should be possible to
identify CIII mutants that would be dominant negative due to
formation of inactive CIIImutant-CIIIwild-type hetrooligomers. To
find such a mutant we introduced, using recombineering [30], a set
of five alanine substitutions into the essential region of CIII within
the l genome. The mutants S17A, R24A, L26A, R27A and R32A
show a cIII
2 phenotype in plaque morphology and in CII activity,
using the pE-GFP fluorescence assay (data not shown). Two
mutants CIIIR27A and CIIIR32A were inserted into a plasmid under
the tac promoter, for further analysis. Next, we confirmed by
electrophoresis that these mutants formed oligomers at efficiency
similar to that of wild type CIII (data not shown). We then tested
their ability to cause dominant negative inhibition of wild type CIII
activity. As shown in Table 1, the plating of wild type phage on
a strain carrying the CIIIR32A plasmid leads to a clear plaque
formation. Consistent with these results, we found reduction in the
frequency of lysogeny from 10% to 0.22% in the strain carrying the
R32A mutant plasmid. These results suggest that the CIIIR32A
mutant inhibits wild type CIII activity and support the hypothesis
that CIII oligomerization enhances FtsH inhibition.
Figure 4. Purified CIII acts as a competitive inhibitor of FtsH. (A)4mM
of CII were incubated with 1 mM GST-FtsH at 42
0C for 5 minutes in the
presence of increasing concentrations (as specified) of His6-CIII. The
reactions were loaded on 4–12% NuPAGE (invitrogen) and visualized by
Coomassie stain. First lane indicates the amount of CII at starting time.
(B) The CII levels remaining after degradation experiment shown in A,
were calculated using the ‘‘NIH image’’ program and plotted versus CIII
levels (full diamonds and full lines). A similar experiment with only 1 mM
of CII being degraded is shown in empty diamonds and a dotted line.
(C) The binding assays were done in the presence of 10mM AMP-PNP as
described in the materials and methods. The reactions were loaded on
4–12% NuPAGE (invitrogen) and visualized by western blotting using
antibodies raised against the CII protein. (D) CII levels bound in complex
to GST-FtsH were calculated using the ‘‘NIH image’’ program and
average from two different experiments was plotted versus CIII levels.
The error bars are +/2 SD.
doi:10.1371/journal.pone.0000363.g004
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bacteriostatic effect of CIII
LpxC catalyses the limiting reaction in lipopolysaccharide biosyn-
thesis and controls the ratio between lipopolysaccharides and lipo-
phospholipids in Gram-negative bacteria. Overproduction of LpxC
causestoxicaccumulationofmembranesintheperiplasm.LpxClevels
are tightly regulated by the FtsH protease, which is therefore an
essential protease in E. coli. [31]. Genetic experiments showed that
sfhC21,amutationthatup-regulatedtheFabAdehydrase(ofthetypeII
fatty acid synthase system) suppresses a deletion in ftsH [31].
It was shown that overexpression of CIII impairs host cell
growth and that this inhibition can be overcome by compensating
high levels of FtsH capable of degrading CIII [13,15,32]. To
identify if FtsH is the sole target responsible for CIII growth
inhibition we constructed a plasmid carrying the pBAD-CIII-GFP
fusion. This construct prevents colony formation when introduced
into a wild type bacterial strain, indicating that the CIII-GFP
fusion protein retains a strong inhibitory effect on cell growth
(Table 2). However expression of CIII-GFP did not impair
bacterial growth of the DftsH sfhC21 double mutant strain or the
sfhC21 single mutant. These findings corroborate the results shown
by Ogura et al. [31] which demonstrated that the primary target of
CIII in inhibiting cellular growth is FtsH proteolytic activity.
DISCUSSION
The phage l decision-making process has been studied extensively
as a paradigm for genetic networks. The l CIII inhibitor peptide is
required for efficient lysogenic activation following phage in-
fection. In this work we describe biochemically and genetically
properties of this FtsH inhibitor. We identified similarities between
CIII and the Bacillus SpoVM FtsH inhibitory peptide. Both
inhibitors are degraded by FtsH and are found in association with
the cell membrane [10,11]. We found that CIII, as SpoVM, forms
an amphipathic a helix. Sequence similarities suggest that the
relatively conserved amphipathic a helix may be important for the
inhibitory activity of both peptides.
Figure 5. FtsH and HflA affect the l genetic network. CII activity is reported by pE-gfp fusions (blue diamonds), whereas Q activity is reported by
pR‘-tR‘-gfp fusions (red circles). The promoter activity as function of time of cultures of wild type strain (A, D, G) hflA- strain (B, E, H)o rftsH deleted
strain (C, F, I) infected with lc+ (A, B, C), lcIII
2 (D, E, F) and lcII
2 (G, H, I) is shown. All experiments were carried out as described in the materials and
methods at a MOI of 6.
doi:10.1371/journal.pone.0000363.g005
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ing number of temperate phages. As FtsH is highly conserved in
prokaryotic organisms as well as in the mitochondria and the
chloroplasts of eukaryotic cells, one might expect that the inhibi-
tory function of this protease will also be conserved. However, no
CIII-like proteins are found to be present in the genome database.
It is possible that CIII-like functions having different primary
sequences do exist or less likely, efficient temporal inhibition of
FtsH did not find its use in bacterial evolution.
Both CII and CIII are tightly regulated at the levels of tran-
scription and translation [19]. By inhibiting FtsH, CIII leads to an
increase in the levels of CII activity. Thus, the CII/CIII/FtsH/
HflKC act as a post-translational regulatory module (Figure 8A).
Here we found that CIII acts as a competitive inhibitor of the host
FtsH interfering with the binding of the CII substrate to the
enzyme.
A number of biochemical properties of the CII/CIII/FtsH/
HflKC module (Figure 8B) provide for its ability to finely tune CII
levels, thus to tightly control the lysis-lysogeny decision. First, the
FtsH/HflKC is present in the cell as huge, membrane-bound,
highly active enzyme complexes, FtsH6HflKC6 of which there are
probably less the 100 molecules in a cell [16]. Furthermore, FtsH
degrades CII very rapidly without requiring adaptor or chaperone
functions [33]. The CIII inhibitor is also subject to proteolysis by
FtsH, which limits its activity to a short time window and allows
for its rapid elimination once the lysogenic state is established. The
Figure 6. CIII levels effect on CII and Q activity in vivo. CII activity is
reported by pE-gfp fusions (blue diamonds), whereas Q activity is
reported by pR‘-tR‘-gfp fusions (red circles). Promoter activity is given as
a function of time of infected cultures carrying the pCTCIII plasmid in
the presence or absence of 0.1mM IPTG (B, D, F or A, C, E respectively)
with lc+ (A, B), lcIII
2 (C, D), and lcII
2 (E, F). All measurements were
carried out as described in the materials and methods at a MOI of 6.
doi:10.1371/journal.pone.0000363.g006
Figure 7. CIII levels affect multiplicity of infection. The total
fluorescences obtain from the pE-GFP plasmid, 80 minutes after
infection were plotted against the MOI of each experiment. lcIII
2
infections of bacteria carrying the pCTCIII plasmid were followed in the
absence (light blue squares) or presence of 0.1 mM IPTG (blue squares)
or of 0.2 mM IPTG (purple squares). lc+ (red6symbol) and lcIII
2
(orange6symbol) infections of bacteria without the pCTCIII plasmid are
shown as reference.
doi:10.1371/journal.pone.0000363.g007
Table 1. The dominant negative effect of CIII mutants as
observed by plaque morphology.
......................................................................
Strain l c+ l cIII67 l cII68
AD16 T C C
AD16/pQECIII T T C
AD16/pQECIIIR27A TCC
AD16/pQECIIIR32A CCC
AD16 strains carrying plasmids expressing wild type and mutated CIII via tac
promoter were grown overnight at 32uC in LB or LB supplemented with
100 mg/ml ampicillin. A lawn of each strain was plated on TB plates in the
presence of 10 mM IPTG and then spotted by different concentrations of the


























































The ability to grow on LB plates was tested in a set of isogenic strains of W3110
(Wild Type strain). To these strain the CIII-GFP plasmid was inserted by
electroporation and the ability to form ampicillin resistant colonies was tested
either at 30uCo r3 7 uC by plating on LB plates with 100 mg/ml ampicillin in the
absence of arabinose. The plus sign represent growth whereas the minus sign
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host. Our results suggest that FtsH is the only target of CIII
responsible for the bacteriostatic effect of CIII.
The structure-function relationships of CIII are not known. The
role of the amphipathic region may be for improved binding to
FtsH or for the interaction with the cytoplasmic membrane favor-
ing its binding to the membrane-bound FtsH [11]. We identified
the ability of CIII to form oligomers, which may interact via the
predicted coiled coil motif of this amphipathic region. The domi-
nant negative effect of the CIIIR32A mutant over the wild type CIII
strongly suggests that CIII functions in vivo in oligomeric form.
Many proteins of bacteriophage l are regulated by rapid
proteolysis by various proteases [5]. Interestingly, the key elements
of the lysis lysogeny decision, the CII and CIII proteins, are mainly
degraded by FtsH. We suggest that coevolutionary forces main-
taining the balance between bacteria and the infecting phages
preferred cells that carry the active protease critical for the
regulation of lysis-lysogeny decision. The fittest mechanism was
obtained by selecting the only essential ATP-dependent protease
in E. coli.
MATERIALS AND METHODS
Bacterial strains and plasmids
The ftsH deletion strain is W3110 sfhC ZAD220::Tn10 ftsH3::KanR
[31]. The hflK mutant strain is W3110 hflK::KanR prepared by P1
transduction. AD16 is strain carrying lacI
q [34] The expression
systems and purification processes of the FtsH, CII and CIII
proteins were described before [12]. The CIII-GFP plasmid was
constructed by insertion of the CIII gene into the pJHK5 plasmid
(received from Marcia Goldberg) using the EcoRI and PstI
restrictions sites for the 59 and 39 respectively. The lambda
promoters-GFP fusion plasmids [28] were used for monitoring the
lambda infection process. Plasmid pCTCIII [35] carries the l cIII
gene downstream of the pTac promoter such that expression of the
l cIII gene can be conditionally induced by addition of the
isopropyl-thio-b-D-galactopyranoside (IPTG) inducer. The point
mutations in the cIII gene were introduced using single strand
DNA oligos as described [30] and selected by formation of clear
plaques. The mutations were confirmed by sequencing. The cIII
mutant genes were amplified by PCR and cloned into the pQE30
plasmid (Qiagen) as described for the wild type CIII [12].
Fluorescence assays
Strains carrying both one of the promoter-gfp plasmids and the
pCT-CIII plasmid were grown overnight in LB medium
supplemented with 0.2% maltose, 50 mg/ml ampicillin and
20 mg/ml chloramphenicol. Cells were concentrated by centrifu-
gation to 6610
9 cells per ml, and 25 ml samples then were infected
with different amounts of freshly prepared phage lysates (at the
specified MOI) on ice. After incubation for 30 min on ice, the
infected cells were diluted to 0.5 ml in M9 supplemented with
0.5% glycerol, 0.2% maltose, 0.01% B1, 50 mg/ml ampicillin and
20 mg/ml chloramphenicol, in the presence or absence of
isopropyl -D-thiogalactoside (IPTG) as specified. Immediately
after dilution, 200 ml cultures (6610
7 cells) were assayed in
duplicates in 96-well plates for GFP activity. Plates were incubated
at 37uC and assayed at 2-min intervals in a SPECTRAFluor Plus
fluorimeter (Tecan, Maennedorf, Switzerland) with a short
shaking interval between assays. The FtsH and HflK mutants
experiments were done similarly with the exception that no
chloramphenicol or IPTG were used in these experiments. The
data analysis was carried out as described based on the average of
two experiments [28].
Circular Dichroism
The CD spectra (wavelengths 195–255nm) of a highly purified
preparation of the His6-CIII diluted in PBS solution were recorded
in a 0.5 mm path-length cuvette at 37uC on a Jobin et Yvon CD 6
spectropolarimeter with sampling intervals of 1 nm. The average
of six scans is shown after smoothing the data by averaging each
wavelength point with the previous two and next two points.
In vitro assays
Proteolysis assays of GST-FtsH were performed as described [33].
Cross-linking reactions contained 4 mM CII, 1 mM GST-FtsH,
CIII in different concentrations and 0.1mg/ml BSA in PBS
Figure 8. Schematic model for CIII activity. (A) The role of the CIII/CII/
FtsH/HflKC module in the lambda genetic decision. The FtsH and HflKC
complex regulates CII and CIII levels and CIII controls FtsH/HflKC
proteolytic activity. (B) A schematic drawing of the CIII mechanism of
inhibition (based on the model presented in [16]). In panel 1 in the
absence of CIII, CII binds the FtsH protease and is translocated into the
enzymatic cavity where it is first unfolded and then degraded. In panel
2, CIII binds the FtsH protease and prevents CII from binding. In panel 3,
the CIII protein, which is found as an oligomer, is also subjected to
degradation.
doi:10.1371/journal.pone.0000363.g008
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of 10mM AMP-PNP (no nucleotide dependence was observed) for
5 minutes at 42uC. 0.25% Glutaraldehyde was added and the
reaction was incubated for two more minutes at 42uC and
terminated by the addition of glycine to a final concentration of
200 mM and transferring the reaction mix to 0uC. For CIII
oligomerization 10 mM of His6-CIII were incubated in PBS
solution with 0.1 mg/ml BSA at 42uC. The cross-linking reaction
started by addition of 0.25% Glutaraldehyde and was stopped by
200 mM Glycine and transferring the reaction mix to 0uC.
Frequency of lysogeny assay
Bacterial cultures (AD16; AD16/pCIIIR32A) were grown, in LB
medium and in LB-ampicilin medium, respectively. l c+ kn
R phage
[12] was adsorbed on ice for 30 min, at a multiplicity of 0.01. The
infected cells were diluted into LB medium in the presence of
10 mM IPTG isopropyl b-d-thiogalactoside and incubated at 37uC
for 45 min before spreading on LB plates containing 30 mg/ml
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